4.3 Article

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3-LBA and immunogenicity)

期刊

BIOANALYSIS
卷 6, 期 24, 页码 3355-3368

出版社

FUTURE SCI LTD
DOI: 10.4155/bio.14.283

关键词

-

资金

  1. US FDA
  2. Europe EMA
  3. Health Canada
  4. France ANSM
  5. The Netherlands MEB
  6. Austria AGES
  7. Germany BfArM
  8. Japan MHWL
  9. UK MHRA

向作者/读者索取更多资源

The 2014 8th Workshop on Recent Issues in Bioanalysis (8thWRIB), a 5-day full immersion in the evolving field of bioanalysis, took place in Universal City, California, USA. Close to 500 professionals from pharmaceutical and biopharmaceutical companies, contract research organizations and regulatory agencies worldwide convened to share, review, discuss and agree on approaches to address current issues of interest in bioanalysis. The topics covered included both small and large molecules, and involved LCMS, hybrid LBA/LCMS, LBA approaches and immunogenicity. From the prolific discussions held during the workshop, specific recommendations are presented in this 2014 White Paper. As with the previous years' editions, this paper acts as a practical tool to help the bioanalytical community continue advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2014 edition of this comprehensive White Paper has been divided into three partsfor editorial reasons. This publication (Part 3) covers the recommendations for Large molecules bioanalysis using LBA and Immunogenicity. Part 1 (Small molecules bioanalysis using LCMS) and Part 2 (Hybrid LBA/LCMS, Electronic Laboratory Notebook and Regulatory Agencies' Input) were published in the Bioanalysis issues 6(22) and 6(23), respectively.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据